All research presented at ACG 2025 is strictly embargoed until 12:00 pm local Arizona Time, which aligns with Pacific Daylight Time (PDT)/3:00 pm ET on Sunday, October 26, 2025.
P0616 – Bone Density and Fracture Risk in Vonoprazan Users: A Stratified Population-Based Analysis
Sunday, October 26, 2025 | 3:30 PM – 7:00 PM PDT | Exhibit Hall
Author Insight from Morgan Starkey, MD
What’s new here and important for clinicians?
While our study found that vonoprazan does not significantly increase the risk of bone density loss in the general population, subgroup analysis showed that female users faced a significantly higher risk compared to males. Age did not play a significant factor, but those older than 50 had a slightly higher risk.
Most importantly, even though there was no overall significant link between vonoprazan and reduced bone density, users who developed osteopenia or osteoporosis experienced a notably higher rate of fragility fractures. This should be taken into serious consideration in starting or continuing use in postmenopausal women, particularly those with already low bone density.
What do patients need to know?
While vonoprazan is superior in the treatment of multiple upper gastrointestinal issues, use should be limited to minimal effectiveness time in postmenopausal women to reduce the risk of bone thinning and life-threatening fractures.
Author Contact
Morgan Starkey, MD
MetroHealth Medical Center
Aurora, OH
morgstarkey415 [at] gmail.com
For assistance contacting other ACG experts, please contact Becky Abel, ACG’s Senior Communications Manager, at mediaonly [at] gi.org.